Weight Loss Medications for Adult Patients With Obesity and Binge Eating—A Systematic Review and Meta-analysis
Authors' conclusion
Liraglutide was an effective intervention for weight loss in patients with obesity who experience BE. The use of liraglutide and naltrexone/bupropion as seen in individual studies may be an effective intervention to improve BE severity in this population; however, meta-analysis was not feasible due to the heterogeneous assessment tools used to measure response in BE episodes. Larger randomized and prospective studies with a longer follow-up are needed to evaluate the consistency of the data presented in this review.
Study context
- Population
- Adults with obesity and binge eating; mostly women (>63%), mean age 45 years, BMI 35 to 40 kg/m²
- Participants
- 231 / 378 / 448
- Comparison
- Approved weight loss medications for binge eating in obesity
- Liraglutiden = 231
- Naltrexone/bupropionn = 378
- Orlistatn = 448
- Outcome
- Binge eating episodes
Pooled result
As reported in the abstract
- Liraglutide: reduction in binge eating (BE) episodes in most individual studies, not statistically significant in the meta-analysis
- Naltrexone/bupropion: reduced BE episodes in individual studies; inconsistent reporting limited pooled analysis
- Orlistat: no significant effect on BE episodes
Further pooled results
- Liraglutide: greater weight loss
- −4.95 kg [−7.12, −2.77]
- Orlistat: no significant effect on weight loss
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →